DUSA PHARMACEUTICALS, INC. et al v. BIOFRONTERA INC. et al

3:23-cv-20601NjdFeb 18, 2026

Full text

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
DUSA PHARMACEUTICALS, INC.,
SUN PHARMACEUTICAL
INDUSTRIES, INC., and SUN
PHARMACEUTICAL
INDUSTRIES, LTD.,
Plaintiffs,
v.
BIOFRONTERA INC., BIOFRONTERA
BIOSCIENCE GMBH, BIOFRONTERA
PHARMA GMBH, and BIOFRONTERA
AG,
Defendants.
Civ. No. 23-20601 (RK)(JBD)
MEMORANDUM ORDER
Plaintiffs Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical
Industries, and DUSA Pharmaceuticals, Inc. (“Sun”) move for leave to file a second
amended complaint. [Dkt. 285.] Defendants Biofrontera, Inc., Biofrontera AG,
Biofrontera Bioscience GmbH, and Biofrontera Pharma GmbH (collectively,
“Biofrontera”) oppose the motion. [Dkt. 290.] The Court has carefully considered
the parties’ positions and, for the reasons set forth below, GRANTS the motion to
amend.
I. 	BACKGROUND
The Court assumes familiarity with the matter and recites only the facts
relevant to the present motion. The parties are competing producers of devices and
drugs used in photodynamic therapy for the treatment of certain skin diseases.
This case arises from the alleged breach of a settlement agreement entered on
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 1 of 13 PageID:
<pageID>
2
November 29, 2021, which resolved earlier litigation between the parties in the
United States District Court for the District of Massachusetts. Relevant here, the
agreement
[Dkt. 52] ¶ 55.
In this case, Sun alleges that Biofrontera breached
First, in the operative amended complaint filed on November 13, 2023 [Dkt. 52],
Sun alleged that Biofrontera made impermissible promotional statements that
suggested or implied that Ameluz may be used to treat cancerous or precancerous
cells beyond actinic keratoses. Id. ¶ 59. Second, Sun alleged that Biofrontera made
impermissible promotional statements that suggested or implied that Ameluz may
be used to treat subclinical actinic keratosis. Id. Those promotional claims, Sun
alleged, constituted off-label marketing of Biofrontera’s products, in violation of
federal and state law and
The Court held an initial scheduling conference on May 1, 2024 with Sun and
defendant Biofrontera Inc., the only Biofrontera defendant for which service had
been perfected at that time. The Court issued a scheduling order on May 3, 2024,
directing that Sun and Biofrontera, Inc. begin discovery. [Dkt. 88.] From its
inception, fact discovery has been hotly disputed, requiring the Court’s resolution of
numerous disputes. Meanwhile, service upon the German Biofrontera defendants
was completed in March 2025, see [Dkt. 177], and those defendants appeared and
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 2 of 13 PageID:
<pageID>
3
began discovery in June 2025. Given the discovery disputes that have arisen, and
the delays precipitated by service of process on the German Biofrontera defendants,
the Court has revised and extended the fact discovery schedule several times.
Despite those revisions, the Court never changed the original June 7, 2024 deadline
to file a motion to amend the pleadings set forth in the initial scheduling order.
Under the present schedule (entered on November 14, 2025), fact discovery closes
on March 5, 2026 and expert discovery closes in July 2026. [Dkt. 295.] A date for
trial has not yet been set.1
In January 2025, the parties first presented to the Court a significant dispute
regarding the scope of Sun’s claims in this case and, therefore, the scope of
discovery. [Dkt. 151.] Sun took the position that the two examples of off-label
promotion described above were merely that, and did not limit its ability to recover
for other types of unlawful off-label promotion in which it alleged Biofrontera had
engaged. Biofrontera disagreed and argued that
the scope of the case is limited to those two categories.
Concretely, this dispute arose because Sun asserts that in addition to the two
categories of off-label promotion identified above, Biofrontera also engaged in
1 	Sun recently moved to disqualify the law firm representing Biofrontera in
this case. [Dkt. 317.] That motion likely will require further amendment to the
current schedule.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 3 of 13 PageID:
<pageID>
4
prohibited off-label promotion by providing samples of Ameluz to doctors who did
not have the specific Biofrontera lamps for which Ameluz is approved. (Ameluz is
approved for use only in conjunction with those lamps.) In this way, Sun alleges,
Biofrontera engaged in additional off-label promotion in violation of federal and
state law and 	The Court will hereafter refer to
this theory of unlawful promotional activity as the “sampling theory,” the “sampling
allegations,” or the “sampling claims.” Biofrontera denies the sampling allegations
in general but, more fundamentally, asserts that they are not properly a part of this
case.
On June 10, 2025, after receiving multiple submissions and hearing multiple
rounds of argument from counsel on the dispute, the Court permitted Sun to obtain
narrowly targeted discovery from Biofrontera on the sampling allegations.
See [Dkt. 177] (March 12, 2025 order formalizing February 25, 2025 oral rulings
directing Sun, as relevant here, to substantially narrow its discovery requests
related to sampling); [Dkt. 252] (August 15, 2025 order formalizing June 10, 2025
oral rulings permitting sampling discovery). The Court did so without answering
the questions whether Sun’s sampling theory falls outside the scope of the case or
the amended complaint, and whether the theory is otherwise cognizable.
The Court’s August 15 order expressly noted that all of Biofrontera’s objections to
Sun’s sampling theory and allegations are preserved. [Dkt. 252.] Since June 2025,
the parties have engaged in discovery on the sampling allegations, and disputes
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 4 of 13 PageID:
<pageID>
5
have arisen on that subject. [Dkt. 307.]2 According to Sun, the sampling evidence
disclosed to date reflects a substantial evidentiary basis from which to conclude that
Biofrontera has indeed engaged in prohibited off-label promotional activity through
its sampling practices. Biofrontera disagrees.
Given all this, Sun now moves to amend the complaint to add the sampling
allegations, making explicit what it believes is already part of the case. Biofrontera
opposes the motion.
II. 	LEGAL STANDARDS
“’The threshold issue in resolving a motion to amend is the determination of
whether the motion is governed by Rule 15 or Rule 16 of the Federal Rules of Civil
Procedure.’” Park v. Freehold Healthcare, LLC., Civ. No. 18-11306 (JBC), 2022 WL
19558164, at *1 (D.N.J. Feb. 15, 2022) (quoting Karlo v. Pittsburgh Glass Works,
LLC, Civ. No. 10-1283 (NBF), 2011 WL 5170445, at *2 (W.D. Pa. Oct. 31, 2011)).
Rule 15 states, in pertinent part, that “a party may amend its pleading only with
the opposing party’s written consent or the court’s leave. The court should freely
give leave when justice so requires.” Fed. R. Civ. P. 15(a)(2). This liberal standard
reflects a preference “that claims will be decided on the merits rather than on
technicalities.” Arista Recs., Inc. v. Flea World, Inc., 356 F. Supp. 2d 411, 419
(D.N.J. 2005) (citations omitted). Accordingly, the Court may deny a motion to
amend only where there is (i) undue delay; (ii) bad faith or dilatory motive;
2 	The Court does not resolve here the pending discovery dispute related to
sampling. The Court will do so in due course.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 5 of 13 PageID:
<pageID>
6
(iii) undue prejudice; (iv) repeated failures to cure deficiencies; or (v) futility of
amendment. Foman v. Davis, 371 U.S. 178, 182 (1962); Long v. Wilson, 393 F.3d
390, 400 (3d Cir. 2004) (“We have held that motions to amend pleadings [under
Rule 15(a)] should be liberally granted.”) (citation omitted).
“Rule 16, on the other hand, requires a party to demonstrate ‘good cause’
prior to the Court amending its scheduling order.” Karlo, 2011 WL 5170445, at *2
(citing Fed. R. Civ. P. 16(b)(4)). Where a party seeks to amend “after the deadline
set by the Court, the movant must satisfy the [good cause standard] of Rule 16
before the Court will turn to Rule 15.” Id. at *2. A determination of “good cause”
under Rule 16 depends on the diligence of the moving party. GlobespanVirata, Inc.
v. Texas Instruments Inc., Civ. No. 03-2854 (GEB), 2005 WL 1638136, at *3
(D.N.J. July 12, 2005) (citations omitted). Specifically, to demonstrate “good cause”
pursuant to Rule 16, the moving party must show that, despite its diligence, the
deadlines set forth in the scheduling order could not reasonably be met. Id.
The mere absence of prejudice to the non-moving party does not constitute
“good cause” under Rule 16. Id.
Whether Rule 16’s good cause standard applies and has been satisfied in any
given case, and the ultimate determination whether to permit amendment under
Rule 15, are decisions left to the Court’s sound discretion. Fraser v. Nationwise
Mut. Ins. Co., 352 F.3d 107, 116 (3d Cir. 2003).
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 6 of 13 PageID:
<pageID>
7
III. 	DISCUSSION
A. 	Rule 16
Under the circumstances, the Court will not require Sun to satisfy Rule 16’s
more stringent good-cause standard because the Court agrees with the reasoning in
In re: L’Oreal Wrinkle Cream Marketing Pracs. Litig., Civ. No. 12-3571 (MF), 2015
WL 5770202, at *3 (D.N.J. Sept. 30, 2015), and Batta v. HCL Am., Inc., Civ No. 17-
5988 (JBC), 2019 WL 6888407, at *2 (D.N.J. Dec. 17, 2019), and applies that
reasoning here. Specifically, the Court has extended the deadline to complete fact
discovery multiple times in light of the service issues, the delayed entry of the
German Biofrontera defendants into the case, and the numerous discovery disputes
that have arisen throughout fact discovery. Indeed, the Court did not find the
German Biofrontera defendants served until about eight months after the
amendment deadline, and the German Biofrontera defendants did not begin
discovery until more than a year after the deadline. As in L’Oreal and Batta,
“[i]t would be illogical to hold [Sun] to an amendment deadline date in a scheduling
order that long ago went stale.” L’Oreal, 2015 WL 5770202 at *3. Accordingly, the
Court turns to Rule 15.
B. 	Rule 15
Biofrontera argues that this Court should deny Sun’s motion because the
proposed amendment is futile and the product of undue delay that will cause undue
prejudice. The Court is not persuaded. In light of Rule 15’s liberal policy of
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 7 of 13 PageID:
<pageID>
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 8 of 13 PageID:
<pageID>
9
544, 570 (2007); Harrison Beverage Co. v. Dribeck Imps., Inc., 133 F.R.D. 463, 468
(D.N.J. 1990) (“‘Futility’ of amendment is shown when the claim or defense is not
accompanied by a showing of plausibility sufficient to present a triable issue.”).
Importantly, however, while Rule 15 futility tracks Rule 12(b)(6)’s
plausibility standard, it does not contemplate full-blown motion practice on the
merits of the claims: “If a proposed amendment is not clearly futile, then denial of
leave to amend is improper. This does not require the parties to engage in the
equivalent of substantive motion practice upon the proposed new claim or defense.”
Harrison Beverage Co., 133 F.R.D. at 468-69 (quoting 6 Wright & Miller’s Federal
Practice & Procedure § 1487 (2d ed. 1990)). The proposed amended pleading,
rather, must “appear to be sufficiently well-grounded in fact or law that it is not a
frivolous pursuit.” Id. Effectively, this means that the proposed amendment must
not be “frivolous or advance[] a claim or defense that is legally insufficient on its
face . . . .” Id.
The Court will not deny Sun’s motion to amend as futile. That is not to reject
Biofrontera’s legal arguments on the merits, and the undersigned states no view on
the matter. As to the sufficiency of the allegations underlying the Massachusetts
statutory claims, the Court concludes only that the proposed second amended
complaint is not clearly futile and appears sufficiently well grounded in fact and law
such that it is not a frivolous pursuit.
As to sampling, Sun consistently has maintained that its sampling
allegations are and have been part of the case, whether specified in its pleading or
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 9 of 13 PageID:
<pageID>
10
not. The proposed amendment, in Sun’s view, is simply to make that claim explicit
and leave no doubt that the claim is properly asserted in this case. In permitting
discovery on sampling issues to proceed earlier this year, the Court noted that
Biofrontera’s objections to Sun’s sampling theory would be preserved. [Dkt. 252.]
In permitting Sun now to assert the sampling theory expressly in its pleading,
the Court takes the same approach: Biofrontera’s legal challenges to Sun’s
sampling claims remain preserved. Deferring resolution of those challenges in this
fashion is in the interest of judicial efficiency. The Court recently administratively
terminated the German Biofrontera defendants’ motion to dismiss the amended
complaint pending resolution of this motion. [Dkt. 311.] In their motion to dismiss,
the German Biofrontera defendants raised, among other arguments, the same
that Biofrontera raises here, albeit in a
slightly different context. See [Dkt. 228] at 15-19 (arguing that dismissal is
warranted because Sun did not specifically name the German Biofrontera
defendants during the 	). Addressing Biofrontera’s
in two
separate motions makes little sense.
Given all this, the resolution of Biofrontera’s arguments as to Sun’s sampling
allegations and its Massachusetts statutory claim is best deferred for a future
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 10 of 13 PageID:
<pageID>
11
motion on the merits. Biofrontera’s positions on these issues remain preserved
until that time.4
2. 	Undue Delay/Prejudice
The Court also is not convinced that Sun’s motion to amend is the product of
undue delay or that amendment will cause Biofrontera undue prejudice.
The parties spend much time faulting each other for the putative delay.
On one hand, Biofrontera argues that Sun sat on its sampling allegations until the
late stages of fact discovery, despite having known of its theory for years. On the
other hand, Sun argues that Biofrontera caused the delay by refusing for more than
a year to produce discovery related to the sampling allegations, and that it could not
realistically have brought the motion until it obtained sufficient information to
support the claims. This debate is largely immaterial to the Court’s analysis,
however, because the Court does not view Sun’s motion as unduly delayed in any
event. As described above, the parties first brought the sampling dispute to the
Court’s attention in January 2025 as a discovery dispute originating from Sun’s
initial discovery requests, propounded at the onset of discovery in 2024. The Court
4 	In light of the procedural posture of the case and the Court’s preliminary
views of the German Biofrontera defendants’ motion to dismiss expressed during
the December 1, 2025 telephone conference, see generally [Dkt. 311], the
undersigned encourages Biofrontera to consider deferring its preserved challenges
until summary judgment. If, however, Biofrontera seeks to renew the Rule 12
challenges that the Court administratively terminated or to pursue new ones in
response to the forthcoming second amended complaint, the Court reminds
Biofrontera to follow the District Judge’s individual preferences regarding pre-
motion conferences. Regardless, in light of the pending motion to disqualify
Biofrontera’s counsel, see supra note 1, Biofrontera’s deadline to respond to the
second amended complaint is stayed until further notice.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 11 of 13 PageID:
<pageID>
12
spent the better part of the first half of 2025 addressing that discovery dispute,
ultimately directing in June 2025 (and formalizing in an August 2025 written order)
that targeted discovery concerning Biofrontera’s sampling practices would be
permitted. Since that time, the parties have engaged in that discovery, fully
apprised that Sun believed the sampling theory was part of the case even without
amendment. Disputes have arisen regarding that discovery, and the Court will
address them in due course. Given the context and chronology of the sampling
dispute and in view of the case’s overall lifespan, the Court does not think that Sun
brought its motion too late.
As to prejudice, the Court also concludes that permitting the amendment will
not cause Biofrontera any significant evidentiary prejudice. As just noted, the
parties have, at the Court’s direction, engaged in document and deposition discovery
on the sampling allegations. That discovery is ongoing, the parties have not yet
reached expert discovery, and a trial date has not been set. Moreover, the operative
pretrial schedule will likely be amended for reasons unrelated to the present
motion, see supra note 1, and so the parties will have time enough to address any
additional discovery needed to support their claims and defenses regarding the
sampling allegations. To be clear, the Court need not and does not determine here
whether additional discovery on the sampling allegations is necessary or
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 12 of 13 PageID:
<pageID>
13
appropriate; the point is that any additional discovery that is needed will not
significantly impede the orderly completion of discovery or resolution of the case.5
All things considered, the Court concludes that Sun’s proposed amendment is
not the product of undue delay and will not cause undue prejudice to Biofrontera.
IV. 	CONCLUSION
Sun’s motion for leave to file a second amended complaint [Dkt. 285] is
GRANTED. Sun shall file the second amended complaint on or before January 27,
2026. Biofrontera’s deadline to answer, move, or otherwise respond to the second
amended complaint is STAYED pending further order of the Court. The parties are
directed to meet and confer regarding appropriate redactions to this Order and, no
later than February 4, 2026, email chambers a proposed redacted version of this
Order, consistent with applicable law, for public docketing.
IT IS SO ORDERED this 22nd day of January, 2026.
5 	The Court also finds Biofrontera’s stated fear of evidentiary prejudice in the
form of lost documents and faded memories to be too speculative to warrant denial
of the motion.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 13 of 13 PageID:
<pageID>

OCR transcription for search; preserved printed pages are authoritative

Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 1 of 13 PagelD:
<pagelD>

UNITED STATES DISTRICT COURT

DISTRICT OF NEW JERSEY
DUSA PHARMACEUTICALS, INC., Civ. No. 23-20601 (RK)(JBD)
SUN PHARMACEUTICAL
INDUSTRIES, INC., and SUN MEMORANDUM ORDER

PHARMACEUTICAL
INDUSTRIES, LTD.,

Plaintiffs,

V.

BIOFRONTERA INC., BIOFRONTERA
BIOSCIENCE GMBH, BIOFRONTERA
PHARMA GMBH, and BIOFRONTERA
AG,

Defendants.

Plaintiffs Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical
Industries, and DUSA Pharmaceuticals, Inc. (“Sun”) move for leave to file a second
amended complaint. [Dkt. 285.] Defendants Biofrontera, Inc., Biofrontera AG,
Biofrontera Bioscience GmbH, and Biofrontera Pharma GmbH (collectively,
“Biofrontera”) oppose the motion. [Dkt. 290.] The Court has carefully considered
the parties’ positions and, for the reasons set forth below, GRANTS the motion to
amend.

I. BACKGROUND

The Court assumes familiarity with the matter and recites only the facts
relevant to the present motion. The parties are competing producers of devices and
drugs used in photodynamic therapy for the treatment of certain skin diseases.

This case arises from the alleged breach of a settlement agreement entered on

2
November 29, 2021, which resolved earlier litigation between the parties in the
United States District Court for the District of Massachusetts. Relevant here, the
agreement
[Dkt. 52] ¶ 55.
In this case, Sun alleges that Biofrontera breached
First, in the operative amended complaint filed on November 13, 2023 [Dkt. 52],
Sun alleged that Biofrontera made impermissible promotional statements that
suggested or implied that Ameluz may be used to treat cancerous or precancerous
cells beyond actinic keratoses. Id. ¶ 59. Second, Sun alleged that Biofrontera made
impermissible promotional statements that suggested or implied that Ameluz may
be used to treat subclinical actinic keratosis. Id. Those promotional claims, Sun
alleged, constituted off-label marketing of Biofrontera’s products, in violation of
federal and state law and
The Court held an initial scheduling conference on May 1, 2024 with Sun and
defendant Biofrontera Inc., the only Biofrontera defendant for which service had
been perfected at that time. The Court issued a scheduling order on May 3, 2024,
directing that Sun and Biofrontera, Inc. begin discovery. [Dkt. 88.] From its
inception, fact discovery has been hotly disputed, requiring the Court’s resolution of
numerous disputes. Meanwhile, service upon the German Biofrontera defendants
was completed in March 2025, see [Dkt. 177], and those defendants appeared and
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 2 of 13 PageID:
<pageID>

3
began discovery in June 2025. Given the discovery disputes that have arisen, and
the delays precipitated by service of process on the German Biofrontera defendants,
the Court has revised and extended the fact discovery schedule several times.
Despite those revisions, the Court never changed the original June 7, 2024 deadline
to file a motion to amend the pleadings set forth in the initial scheduling order.
Under the present schedule (entered on November 14, 2025), fact discovery closes
on March 5, 2026 and expert discovery closes in July 2026. [Dkt. 295.] A date for
trial has not yet been set.1
In January 2025, the parties first presented to the Court a significant dispute
regarding the scope of Sun’s claims in this case and, therefore, the scope of
discovery. [Dkt. 151.] Sun took the position that the two examples of off-label
promotion described above were merely that, and did not limit its ability to recover
for other types of unlawful off-label promotion in which it alleged Biofrontera had
engaged. Biofrontera disagreed and argued that
the scope of the case is limited to those two categories.
Concretely, this dispute arose because Sun asserts that in addition to the two
categories of off-label promotion identified above, Biofrontera also engaged in
1 	Sun recently moved to disqualify the law firm representing Biofrontera in
this case. [Dkt. 317.] That motion likely will require further amendment to the
current schedule.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 3 of 13 PageID:
<pageID>

4
prohibited off-label promotion by providing samples of Ameluz to doctors who did
not have the specific Biofrontera lamps for which Ameluz is approved. (Ameluz is
approved for use only in conjunction with those lamps.) In this way, Sun alleges,
Biofrontera engaged in additional off-label promotion in violation of federal and
state law and 	The Court will hereafter refer to
this theory of unlawful promotional activity as the “sampling theory,” the “sampling
allegations,” or the “sampling claims.” Biofrontera denies the sampling allegations
in general but, more fundamentally, asserts that they are not properly a part of this
case.
On June 10, 2025, after receiving multiple submissions and hearing multiple
rounds of argument from counsel on the dispute, the Court permitted Sun to obtain
narrowly targeted discovery from Biofrontera on the sampling allegations.
See [Dkt. 177] (March 12, 2025 order formalizing February 25, 2025 oral rulings
directing Sun, as relevant here, to substantially narrow its discovery requests
related to sampling); [Dkt. 252] (August 15, 2025 order formalizing June 10, 2025
oral rulings permitting sampling discovery). The Court did so without answering
the questions whether Sun’s sampling theory falls outside the scope of the case or
the amended complaint, and whether the theory is otherwise cognizable.
The Court’s August 15 order expressly noted that all of Biofrontera’s objections to
Sun’s sampling theory and allegations are preserved. [Dkt. 252.] Since June 2025,
the parties have engaged in discovery on the sampling allegations, and disputes
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 4 of 13 PageID:
<pageID>

5
have arisen on that subject. [Dkt. 307.]2 According to Sun, the sampling evidence
disclosed to date reflects a substantial evidentiary basis from which to conclude that
Biofrontera has indeed engaged in prohibited off-label promotional activity through
its sampling practices. Biofrontera disagrees.
Given all this, Sun now moves to amend the complaint to add the sampling
allegations, making explicit what it believes is already part of the case. Biofrontera
opposes the motion.
II. 	LEGAL STANDARDS
“’The threshold issue in resolving a motion to amend is the determination of
whether the motion is governed by Rule 15 or Rule 16 of the Federal Rules of Civil
Procedure.’” Park v. Freehold Healthcare, LLC., Civ. No. 18-11306 (JBC), 2022 WL
19558164, at *1 (D.N.J. Feb. 15, 2022) (quoting Karlo v. Pittsburgh Glass Works,
LLC, Civ. No. 10-1283 (NBF), 2011 WL 5170445, at *2 (W.D. Pa. Oct. 31, 2011)).
Rule 15 states, in pertinent part, that “a party may amend its pleading only with
the opposing party’s written consent or the court’s leave. The court should freely
give leave when justice so requires.” Fed. R. Civ. P. 15(a)(2). This liberal standard
reflects a preference “that claims will be decided on the merits rather than on
technicalities.” Arista Recs., Inc. v. Flea World, Inc., 356 F. Supp. 2d 411, 419
(D.N.J. 2005) (citations omitted). Accordingly, the Court may deny a motion to
amend only where there is (i) undue delay; (ii) bad faith or dilatory motive;
2 	The Court does not resolve here the pending discovery dispute related to
sampling. The Court will do so in due course.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 5 of 13 PageID:
<pageID>

6
(iii) undue prejudice; (iv) repeated failures to cure deficiencies; or (v) futility of
amendment. Foman v. Davis, 371 U.S. 178, 182 (1962); Long v. Wilson, 393 F.3d
390, 400 (3d Cir. 2004) (“We have held that motions to amend pleadings [under
Rule 15(a)] should be liberally granted.”) (citation omitted).
“Rule 16, on the other hand, requires a party to demonstrate ‘good cause’
prior to the Court amending its scheduling order.” Karlo, 2011 WL 5170445, at *2
(citing Fed. R. Civ. P. 16(b)(4)). Where a party seeks to amend “after the deadline
set by the Court, the movant must satisfy the [good cause standard] of Rule 16
before the Court will turn to Rule 15.” Id. at *2. A determination of “good cause”
under Rule 16 depends on the diligence of the moving party. GlobespanVirata, Inc.
v. Texas Instruments Inc., Civ. No. 03-2854 (GEB), 2005 WL 1638136, at *3
(D.N.J. July 12, 2005) (citations omitted). Specifically, to demonstrate “good cause”
pursuant to Rule 16, the moving party must show that, despite its diligence, the
deadlines set forth in the scheduling order could not reasonably be met. Id.
The mere absence of prejudice to the non-moving party does not constitute
“good cause” under Rule 16. Id.
Whether Rule 16’s good cause standard applies and has been satisfied in any
given case, and the ultimate determination whether to permit amendment under
Rule 15, are decisions left to the Court’s sound discretion. Fraser v. Nationwise
Mut. Ins. Co., 352 F.3d 107, 116 (3d Cir. 2003).
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 6 of 13 PageID:
<pageID>

7
III. 	DISCUSSION
A. 	Rule 16
Under the circumstances, the Court will not require Sun to satisfy Rule 16’s
more stringent good-cause standard because the Court agrees with the reasoning in
In re: L’Oreal Wrinkle Cream Marketing Pracs. Litig., Civ. No. 12-3571 (MF), 2015
WL 5770202, at *3 (D.N.J. Sept. 30, 2015), and Batta v. HCL Am., Inc., Civ No. 17-
5988 (JBC), 2019 WL 6888407, at *2 (D.N.J. Dec. 17, 2019), and applies that
reasoning here. Specifically, the Court has extended the deadline to complete fact
discovery multiple times in light of the service issues, the delayed entry of the
German Biofrontera defendants into the case, and the numerous discovery disputes
that have arisen throughout fact discovery. Indeed, the Court did not find the
German Biofrontera defendants served until about eight months after the
amendment deadline, and the German Biofrontera defendants did not begin
discovery until more than a year after the deadline. As in L’Oreal and Batta,
“[i]t would be illogical to hold [Sun] to an amendment deadline date in a scheduling
order that long ago went stale.” L’Oreal, 2015 WL 5770202 at *3. Accordingly, the
Court turns to Rule 15.
B. 	Rule 15
Biofrontera argues that this Court should deny Sun’s motion because the
proposed amendment is futile and the product of undue delay that will cause undue
prejudice. The Court is not persuaded. In light of Rule 15’s liberal policy of
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 7 of 13 PageID:
<pageID>

Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 8 of 13 PagelD:
<pagelD>

permitting amendment and its preference for resolution of issues on the merits, the
Court will grant Sun’s motion to amend.

1. Futility

Biofrontera argues that Sun’s proposed amendments to add the sampling
allegations are futile for two reasons. First, it argues that Sun’s sampling
ae : Second, as to Sun’s statutory claim under Massachusetts law,
Biofrontera argues that the proposed amendments do not sufficiently plead that
unlawful conduct occurred in Massachusetts.

“Leave to amend a complaint is futile when the complaint as amended would
still be properly dismissed or immediately subject to summary judgment for the
defendant.” Centennial Plaza Prop, LLC v. Trane U.S. Inc., Civ. No. 22-1262
(MAH), 2023 WL 7403640, at *2 (D.N.J. Nov. 9, 2023) (citation omitted).

To determine whether an amendment would be “properly dismissed,” the Court
employs the same standard applied to Rule 12(b)(6) motions to dismiss. In re
Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1434 (8d Cir. 1997). Under this
standard, the question before the Court is not whether the movant will ultimately

prevail on the claim but whether the complaint sets forth “enough facts to state a

claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S.

[Dkt. 290] at 9-

9
544, 570 (2007); Harrison Beverage Co. v. Dribeck Imps., Inc., 133 F.R.D. 463, 468
(D.N.J. 1990) (“‘Futility’ of amendment is shown when the claim or defense is not
accompanied by a showing of plausibility sufficient to present a triable issue.”).
Importantly, however, while Rule 15 futility tracks Rule 12(b)(6)’s
plausibility standard, it does not contemplate full-blown motion practice on the
merits of the claims: “If a proposed amendment is not clearly futile, then denial of
leave to amend is improper. This does not require the parties to engage in the
equivalent of substantive motion practice upon the proposed new claim or defense.”
Harrison Beverage Co., 133 F.R.D. at 468-69 (quoting 6 Wright & Miller’s Federal
Practice & Procedure § 1487 (2d ed. 1990)). The proposed amended pleading,
rather, must “appear to be sufficiently well-grounded in fact or law that it is not a
frivolous pursuit.” Id. Effectively, this means that the proposed amendment must
not be “frivolous or advance[] a claim or defense that is legally insufficient on its
face . . . .” Id.
The Court will not deny Sun’s motion to amend as futile. That is not to reject
Biofrontera’s legal arguments on the merits, and the undersigned states no view on
the matter. As to the sufficiency of the allegations underlying the Massachusetts
statutory claims, the Court concludes only that the proposed second amended
complaint is not clearly futile and appears sufficiently well grounded in fact and law
such that it is not a frivolous pursuit.
As to sampling, Sun consistently has maintained that its sampling
allegations are and have been part of the case, whether specified in its pleading or
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 9 of 13 PageID:
<pageID>

10
not. The proposed amendment, in Sun’s view, is simply to make that claim explicit
and leave no doubt that the claim is properly asserted in this case. In permitting
discovery on sampling issues to proceed earlier this year, the Court noted that
Biofrontera’s objections to Sun’s sampling theory would be preserved. [Dkt. 252.]
In permitting Sun now to assert the sampling theory expressly in its pleading,
the Court takes the same approach: Biofrontera’s legal challenges to Sun’s
sampling claims remain preserved. Deferring resolution of those challenges in this
fashion is in the interest of judicial efficiency. The Court recently administratively
terminated the German Biofrontera defendants’ motion to dismiss the amended
complaint pending resolution of this motion. [Dkt. 311.] In their motion to dismiss,
the German Biofrontera defendants raised, among other arguments, the same
that Biofrontera raises here, albeit in a
slightly different context. See [Dkt. 228] at 15-19 (arguing that dismissal is
warranted because Sun did not specifically name the German Biofrontera
defendants during the 	). Addressing Biofrontera’s
in two
separate motions makes little sense.
Given all this, the resolution of Biofrontera’s arguments as to Sun’s sampling
allegations and its Massachusetts statutory claim is best deferred for a future
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 10 of 13 PageID:
<pageID>

11
motion on the merits. Biofrontera’s positions on these issues remain preserved
until that time.4
2. 	Undue Delay/Prejudice
The Court also is not convinced that Sun’s motion to amend is the product of
undue delay or that amendment will cause Biofrontera undue prejudice.
The parties spend much time faulting each other for the putative delay.
On one hand, Biofrontera argues that Sun sat on its sampling allegations until the
late stages of fact discovery, despite having known of its theory for years. On the
other hand, Sun argues that Biofrontera caused the delay by refusing for more than
a year to produce discovery related to the sampling allegations, and that it could not
realistically have brought the motion until it obtained sufficient information to
support the claims. This debate is largely immaterial to the Court’s analysis,
however, because the Court does not view Sun’s motion as unduly delayed in any
event. As described above, the parties first brought the sampling dispute to the
Court’s attention in January 2025 as a discovery dispute originating from Sun’s
initial discovery requests, propounded at the onset of discovery in 2024. The Court
4 	In light of the procedural posture of the case and the Court’s preliminary
views of the German Biofrontera defendants’ motion to dismiss expressed during
the December 1, 2025 telephone conference, see generally [Dkt. 311], the
undersigned encourages Biofrontera to consider deferring its preserved challenges
until summary judgment. If, however, Biofrontera seeks to renew the Rule 12
challenges that the Court administratively terminated or to pursue new ones in
response to the forthcoming second amended complaint, the Court reminds
Biofrontera to follow the District Judge’s individual preferences regarding pre-
motion conferences. Regardless, in light of the pending motion to disqualify
Biofrontera’s counsel, see supra note 1, Biofrontera’s deadline to respond to the
second amended complaint is stayed until further notice.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 11 of 13 PageID:
<pageID>

12
spent the better part of the first half of 2025 addressing that discovery dispute,
ultimately directing in June 2025 (and formalizing in an August 2025 written order)
that targeted discovery concerning Biofrontera’s sampling practices would be
permitted. Since that time, the parties have engaged in that discovery, fully
apprised that Sun believed the sampling theory was part of the case even without
amendment. Disputes have arisen regarding that discovery, and the Court will
address them in due course. Given the context and chronology of the sampling
dispute and in view of the case’s overall lifespan, the Court does not think that Sun
brought its motion too late.
As to prejudice, the Court also concludes that permitting the amendment will
not cause Biofrontera any significant evidentiary prejudice. As just noted, the
parties have, at the Court’s direction, engaged in document and deposition discovery
on the sampling allegations. That discovery is ongoing, the parties have not yet
reached expert discovery, and a trial date has not been set. Moreover, the operative
pretrial schedule will likely be amended for reasons unrelated to the present
motion, see supra note 1, and so the parties will have time enough to address any
additional discovery needed to support their claims and defenses regarding the
sampling allegations. To be clear, the Court need not and does not determine here
whether additional discovery on the sampling allegations is necessary or
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 12 of 13 PageID:
<pageID>

13
appropriate; the point is that any additional discovery that is needed will not
significantly impede the orderly completion of discovery or resolution of the case.5
All things considered, the Court concludes that Sun’s proposed amendment is
not the product of undue delay and will not cause undue prejudice to Biofrontera.
IV. 	CONCLUSION
Sun’s motion for leave to file a second amended complaint [Dkt. 285] is
GRANTED. Sun shall file the second amended complaint on or before January 27,
2026. Biofrontera’s deadline to answer, move, or otherwise respond to the second
amended complaint is STAYED pending further order of the Court. The parties are
directed to meet and confer regarding appropriate redactions to this Order and, no
later than February 4, 2026, email chambers a proposed redacted version of this
Order, consistent with applicable law, for public docketing.
IT IS SO ORDERED this 22nd day of January, 2026.
5 	The Court also finds Biofrontera’s stated fear of evidentiary prejudice in the
form of lost documents and faded memories to be too speculative to warrant denial
of the motion.
Case 3:23-cv-20601-RK-JBD Document 362 Filed 02/18/26 Page 13 of 13 PageID:
<pageID>

Continue your research in ChatGPT or Claude

Connect Omnilex to search the legal corpus from your AI assistant.